Anthony Fauci likely to retire by the end of Biden’s term

Anthony Fauci likely to retire by the end of Biden’s term


Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, responds to questions from Senator Rand Paul (R-KY) during a Senate Health, Education, Labor, and Pensions Committee hearing to examine the federal response to the coronavirus disease (COVID-19) and new emerging variants at Capitol Hill in Washington, D.C., U.S. January 11, 2022.

Greg Nash | Reuters

Dr. Anthony Fauci will likely retire by the end of President Joe Biden’s term in January 2025.

Fauci has directed the National Institute of Allergy and Infectious Diseases since 1984. He has also served as Biden’s chief medical adviser since January 2021.

“I have always said that sometime in the reasonable future, I would be stepping down,” Fauci told NBC News. “Thus sometime between now and then I very likely will step down and move on to the next phase in my professional career, whatever that may be.”

However, Fauci said “no decision has been made” about precisely when his retirement will begin — he simply views end of Biden’s term as a marker for his retirement planning.

At age 81, he said, “I do not plan to be in this position forever.”

This is a developing story.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More